Long-term Monitoring Helps Maintain Bone Health in Childhood Cancer Survivors

Bone health of children and adolescents treated for cancer can be adversly affected. The review 'Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors' helps clinicians define specific groups at higher risk of long-term bone complications, identify unrecognized long-term adverse effects, and ultimately improve patient care.

This includes a concise diagnostic-therapeutic algorithm which outlines a clinical pathway to aid physicians in the long-term care of their patients.

‘New International Osteoporosis Foundation (IOF) Working Group publication reviews bone complications in childhood cancer survivors and provides evidence-based recommendations for the management of long-term bone health.’

The publication by the International Osteoporosis Foundation (IOF) Cancer and Bone Working Group reviews the latest knowledge in this area of clinical research and provides succinct recommendations for essential long-term follow-up of bone health in childhood cancer survivors. Advances in the treatment of children and adolescents with cancer have led to substantial improvements in survival, with a 5-year survival rate of childhood cancer close to 80%.

Professor Maria-Luisa Brandi, Head of the Bone Metabolic Diseases Unit, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Italy, and lead author of the study, states: "In children and adolescents treated for cancer, the attainment of peak bone mass, which is a fundamental factor affecting bone mass in adulthood, can be negatively affected. Lower bone mineral density and microarchitectural deterioration can persist during adulthood, thereby increasing fracture risk. That is why the bone health of children and adolescents with a cancer history should be carefully monitored, and patients should be informed of possible late complications of their previous medical treatment."

As well as cancer treatments such as chemotherapy, radiotherapy and stem-cell transplantation, factors which contribute to bone mass impairment in childhood cancer survivors include an inadequate diet (especially calcium and vitamin D deficiency); prolonged treatments with glucocorticoids; hormone alterations involving growth hormone and/or gonadal hormones; reduced or absent physical activity, and inflammation and altered secretion of cytokines due to cancer cells.

The review also points to areas where there are substantial knowledge gaps and identifies the need for further research to clarify whether improving bone health in childhood cancer survivors differs from the management of bone disorders in the general population.

Professor Ren� Rizzoli, Chair of the IOF Cancer and Bone Working Group, added: "Cancer treatments in youth have a multifactorial impact on bone fragility and a core objective, both during treatment and once the patient is in remission or cured, is to reduce the impact on future adult bone health. This requires long-term follow up, involving effective transition from pediatric to adult care, as well as good communication between pediatric oncology and primary care. As clinicians we must work together to help to maintain and protect our young patients' skeletal health."



Source: Eurekalert